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Introduction: Transcatheter aortic valve implantation (TAVI) is now a common procedure to treat high-
risk patients with severe aortic stenosis1. The incidence of post-TAVI infective endocarditis is 3.25%, 
but it is associated with high mortality and complications. The most common complication is heart 
failure with a cumulative incidence of 37.1%. Appropriate measures should be taken to prevent infec-
tive endocarditis in post-TAVI patients including adequate antibiotics prophylaxis2.
Case report: We present a patient with history of implanted TAVI in December 2019, a condition af-
ter myocardial infarction and consequent secondary ischemic cardiomyopathy. In August 2020 he 
was hospitalized again at our Clinic because of acute heart failure and fever. Treatment was initiated 
according to guidelines for acute heart failure with non-invasive ventilation. Echocardiography was 
performed (EF 40%), and a severe mitral regurgitation was verified (in two jets, one between A3 and P3 
segment, and the other between A2 and P2 segment, PISA 1.2 cm, EROA 0.7 cm2, MR RV 66 ml) with 
a visible vegetation on the anterior mitral cusp, on the atrial side, measuring 12x6 mm. Paravalvular 
“leak” of artificial aortic valve was visible, which reached the anterolateral papillary muscle with its 
jet, with PHT 423 ms. Also, minor abscess cavity beside artificial aortic valve was detected. S. Aureus 
was isolated from blood cultures, and linezolid was first introduced into the therapy, followed by van-
comycin. Additionally, septic liver embolizations were radiologically verified. The patient’s condition 
gradually deteriorated with volume retention and oliguria, and small doses of dobutamine (5mcg/kg/
min) were administered. Significant clinical improvement was obtained with abundant diuresis and 
improvement in renal function. Patient was emergently transferred to the cardiac surgery by appoint-
ment for the planned surgical treatment of mitral valve endocarditis and TAVI removal with SAVR.
Conclusion: The mortality rate of infective endocarditis is 25%. There is a higher incidence of infective 
endocarditis in those with prosthetic heart valves and cardiac devices. In these cases, urgent surgical 
intervention is necessary.
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